Journal profile · Immunology and Microbiology-General Immunology and Microbiology

Acta Biomedica Scientifica

ISSN 2541-9420 · eISSN 2587-9596 · Scientific Сentre for Family Health and Human Reproduction Problems · Russian Federation

Acta Biomedica Scientifica: fully open access; APC charged, amount not published; review about 7 weeks (community reports); 125 articles in 2025; indexed in Scopus.

Impact factor—No published value
CAS zone—Not in the CAS Journal Ranking
Review timeabout 7 weeksCommunity average
APCCharged, amount not publishedFully open access
Acceptance—No reports yet
Articles per year1252025 · OpenAlex count

Scope

Aims, scope and focus

Acta Biomedica Scientifica is published by Scientific Сentre for Family Health and Human Reproduction Problems. By OpenAlex counts of its recent articles, its largest topics are Human Health and Disease, Legal and Regulatory Analysis and Military Technology and Strategies, together about 38.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

В журнале публикуются оригинальные научные статьи, клинические и экспериментальные результаты исследований по биомедицинским областям, а также обзоры по основным проблемам практики здравоохранения и биомедицинской науки. Журнал ориентирован на специалистов, студентов, аспирантов, исследователей, чьи интересы, область деятельности или учеба связаны с биомедицинской наукой.

From the journal's Aims & Scope

Research area (LetPub): Immunology and Microbiology-General Immunology and Microbiology

Editor-in-chief академик РАН Колесников С.И.Publisher website

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. Human Health and DiseaseMedicine15%
  2. Legal and Regulatory AnalysisSocial Sciences12%
  3. Military Technology and StrategiesEngineering11.9%
  4. Linguistic, Cultural, and Literary StudiesSocial Sciences11.8%
  5. Healthcare Systems and Public HealthMedicine9.9%
  6. Medical and Biological SciencesMedicine8.9%
  7. Neurological Disorders and TreatmentsNeuroscience3.9%
  8. Yersinia bacterium, plague, ectoparasites researchBiochemistry, Genetics and Molecular Biology2.3%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Not covered

Not covered by this edition.

CAS Xinrui Journal Ranking (March 2026)Not covered

Not covered by this edition.

CAS Journal Ranking, previous upgraded edition (December 2023)Not covered

Not covered by this edition.

Database indexing

ScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

Web of SciencePublisher website

Other: РИНЦ, ВИНИТИ

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

CiteScore 2026-06
0.6LetPub ·
SJR 2026-06
0.14LetPub ·
SNIP 2026-06
0.22LetPub ·
h-index
11OpenAlex ·
i10-index
18OpenAlex ·
2-year mean citedness
0.43OpenAlex ·
Share of gold OA articles
0%LetPub ·

Articles by year OpenAlex count · 5,455 in total · the current year is incomplete

YearArticlesOpen accessCitations
20261001006
202512512528
2024180180140
2023126126168
2022189189287
2021194194346

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Average review time (community reports)
about 7 weeksLetPub ·
Submission to publication (journal-reported)
about 7 weeksDOAJ ·
Peer review
Double anonymous peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Fully open accessDOAJ

Every article is open access; authors usually pay an article processing charge (APC).

SourceAPCFee waiverLicenseObserved
DOAJRUB 10,000YesCC BY
LetPubRUB 10,000Yes—

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Submission

Article types and submission policies (journal website)

What to prepare2 items from the author guidelines
Reference style
Vancouver
Cover letter
Required
Publisher website · model-extracted, each line checked against the text
Article types accepted8
  1. краткие сообщенияКраткие сообщения.Length not stated
  2. лекцииЛекции – клинически направленные обзоры, выполненные специалистом широкого профиля, включающие в себя разделы по эпидемиологии, патофизиологии, диагностическим …Length not stated
  3. обзорыВ журнале публикуются оригинальные научные статьи, клинические и экспериментальные результаты исследований по биомедицинским областям, а также обзоры по основны…Length not stated
  4. обзоры литературыОбзоры литературы – имеют более узкую специализированную направленность, чем лекции, и неструктурированное резюме.Length not stated
  5. оригинальные научные статьиВ журнале публикуются оригинальные научные статьи, клинические и экспериментальные результаты исследований по биомедицинским областям, а также обзоры по основны…Length not stated
  6. оригинальные статьиОригинальные статьи – основаны на результатах клинических исследований. Проведение и описание всех клинических исследований должно быть в полном соответствии со…Length not stated
  7. письмо редакторуПисьмо редактору. Содержит не более 500 слов и должно быть направлено на обсуждение определённой статьи, опубликованной в журнале «Acta Biomedica Scientifica».Length not stated
  8. случай из практикиСлучай из практики – информационное сообщение, представляющее сложную диагностическую проблему и описание её решения или редкий клинический случай.Length not stated
Publisher website
Policy excerpts from the journal's websiteOpen access
Open access

Open access journal with print and electronic versions, peer-reviewed. Model summary

Журнал «Acta biomedica scientifica» является научным рецензируемым журналом открытого доступа с публикацией печатной и электронной версий.

Source ↗Publisher website ·

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Profile

Publication details and official links

Publisher
Scientific Сentre for Family Health and Human Reproduction Problems
Country or region
Russian Federation
Language
Russian
ISSN
2541-9420
Electronic ISSN
2587-9596
Official links

FAQ

Frequently asked questions about Acta Biomedica Scientifica

How long does peer review take at Acta Biomedica Scientifica?

Authors report an average review time of about 7 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

What are the manuscript requirements of Acta Biomedica Scientifica?

According to the journal's author guidelines: Reference style: Vancouver; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.

Which databases index Acta Biomedica Scientifica?

According to LetPub and DOAJ records, Acta Biomedica Scientifica is indexed in Scopus and DOAJ. The journal's website also lists Web of Science; that list has not been checked against each database.

Is Acta Biomedica Scientifica open access, and what is the APC?

Acta Biomedica Scientifica is a fully open-access journal. APC charged, amount not published.

Sources and updates

The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .